Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Blinatumomab

Various toxicities followed by off-label use: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Beneduce G, et al. Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers. Cancers 14: 426, No. 2, Feb 2022. Available from: URL: https://www.mdpi.com/2072-6694/14/2/426/pdf Beneduce G, et al. Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers. Cancers 14: 426, No. 2, Feb 2022. Available from: URL: https://​www.​mdpi.​com/​2072-6694/​14/​2/​426/​pdf
Metadaten
Titel
Blinatumomab
Various toxicities followed by off-label use: 3 case reports
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-26399-2

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Oxcarbazepine

Case report

Bevacizumab

Case report

Catequentinib